Trial Review

Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02087904




Registration number
NCT02087904
Ethics application status
Date submitted
13/03/2014
Date registered
14/03/2014
Date last updated
28/08/2019

Titles & IDs
Public title
A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis
Scientific title
A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis
Secondary ID [1] 0 0
2013-003467-60
Secondary ID [2] 0 0
M13-741
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Knee Osteoarthritis 0 0
Medial Compartment Knee Osteoarthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: ABT-981 low dose - 25 mg ABT-981 subcutaneous (SC) every 2 weeks (E2W)

Experimental: ABT-981 medium dose - 100 mg ABT-981 SC E2W

Experimental: ABT-981 high dose - 200 mg ABT-981 SC E2W

Placebo comparator: Placebo - Placebo
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Scores of the Index Knee at Week 16
Assessment method [1] 0 0
The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.
Timepoint [1] 0 0
Baseline, Week 16
Primary outcome [2] 0 0
Change From Baseline in Quantitative Synovitis of the Index Knee at Week 26
Assessment method [2] 0 0
Change in synovitis of the index knee was evaluated using quantitative magnetic resonance imaging (MRI) measurements. MRI quantitative synovitis of the index knee was defined by mean synovial membrane thickness.
Timepoint [2] 0 0
Baseline, Week 26
Primary outcome [3] 0 0
Change From Baseline in Effusion Volume of the Index Knee at Week 26
Assessment method [3] 0 0
Timepoint [3] 0 0
Baseline, Week 26
Primary outcome [4] 0 0
Change From Baseline in Whole-Organ Magnetic Resonance Imaging Score (WORMS) Semi-Quantitative Synovitis/Effusion Score of the Index Knee at Week 26
Assessment method [4] 0 0
Semi-quantitative synovitis/effusion volume WORMS scores were scored as normal (0), \< 33% of maximum estimated distention (1), 33% - 66% of maximum estimated distention (2), or \> 66% of maximum estimated distention (3).
Timepoint [4] 0 0
Baseline, Week 26
Secondary outcome [1] 0 0
Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 16
Assessment method [1] 0 0
The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.
Timepoint [1] 0 0
Baseline, Week 16
Secondary outcome [2] 0 0
Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 26
Assessment method [2] 0 0
The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.
Timepoint [2] 0 0
Baseline, Week 26
Secondary outcome [3] 0 0
Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 52
Assessment method [3] 0 0
The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.
Timepoint [3] 0 0
Baseline, Week 52
Secondary outcome [4] 0 0
Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 26
Assessment method [4] 0 0
The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.
Timepoint [4] 0 0
Baseline, Week 26
Secondary outcome [5] 0 0
Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 52
Assessment method [5] 0 0
The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.
Timepoint [5] 0 0
Baseline, Week 52
Secondary outcome [6] 0 0
Change From Baseline in Global Total Bone Marrow Lesion (BML) Score of the Index Knee Magnetic Resonance Imaging (MRI) at Week 26
Assessment method [6] 0 0
BMLs in 15 regions were measured with MRI, and graded as 0 (normal), 1 (mild; \< 25% of region), 2 (moderate; 25% - 50% of region), or 3 (severe; \> 50% of region). The global total BML score was the sum of the 15 component scores, and ranged from 0 (normal) to 45 (severe).
Timepoint [6] 0 0
Baseline, Week 26
Secondary outcome [7] 0 0
Change From Baseline in Global Total BML Score of the Index Knee MRI at Week 52
Assessment method [7] 0 0
BMLs in 15 regions were measured with MRI, and graded as 0 (normal), 1 (mild; \< 25% of region), 2 (moderate; 25% - 50% of region), or 3 (severe; \> 50% of region). The global total BML score was the sum of the 15 component scores, and ranged from 0 (normal) to 45 (severe).
Timepoint [7] 0 0
Baseline, Week 52
Secondary outcome [8] 0 0
Change From Baseline in Index Knee Intermittent and Constant Osteoarthritis Pain (ICOAP) Scores at Week 16
Assessment method [8] 0 0
The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).
Timepoint [8] 0 0
Baseline, Week 16
Secondary outcome [9] 0 0
Change From Baseline in Index Knee ICOAP Scores at Week 26
Assessment method [9] 0 0
The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).
Timepoint [9] 0 0
Baseline, Week 26
Secondary outcome [10] 0 0
Change From Baseline in Index Knee ICOAP Scores at Week 52
Assessment method [10] 0 0
The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).
Timepoint [10] 0 0
Baseline, Week 52
Secondary outcome [11] 0 0
Change From Baseline In Index Knee Pain Intensity at Week 16
Assessment method [11] 0 0
The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.
Timepoint [11] 0 0
Baseline, Week 16
Secondary outcome [12] 0 0
Change From Baseline In Index Knee Pain Intensity at Week 26
Assessment method [12] 0 0
The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.
Timepoint [12] 0 0
Baseline, Week 26
Secondary outcome [13] 0 0
Change From Baseline In Index Knee Pain Intensity at Week 52
Assessment method [13] 0 0
The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.
Timepoint [13] 0 0
Baseline, Week 52
Secondary outcome [14] 0 0
Change From Baseline in Patient Global Assessment (PGA) of Arthritis of the Index Knee at Week 16
Assessment method [14] 0 0
The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.
Timepoint [14] 0 0
Baseline, Week 16
Secondary outcome [15] 0 0
Change From Baseline in PGA of Arthritis of the Index Knee at Week 26
Assessment method [15] 0 0
The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.
Timepoint [15] 0 0
Baseline, Week 26
Secondary outcome [16] 0 0
Change From Baseline in PGA of Arthritis of the Index Knee at Week 52
Assessment method [16] 0 0
The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.
Timepoint [16] 0 0
Baseline, Week 52
Secondary outcome [17] 0 0
Change From Baseline in Cartilage Volume of the Index Knee at Week 26
Assessment method [17] 0 0
Cartilage volume of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.
Timepoint [17] 0 0
Baseline, Week 26
Secondary outcome [18] 0 0
Change From Baseline in Cartilage Volume of the Index Knee at Week 52
Assessment method [18] 0 0
Cartilage volume of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.
Timepoint [18] 0 0
Baseline, Week 52
Secondary outcome [19] 0 0
Change From Baseline in Cartilage Thickness of the Index Knee at Week 26
Assessment method [19] 0 0
Cartilage thickness of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.
Timepoint [19] 0 0
Baseline, Week 26
Secondary outcome [20] 0 0
Change From Baseline in Cartilage Thickness of the Index Knee at Week 52
Assessment method [20] 0 0
Cartilage thickness of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.
Timepoint [20] 0 0
Baseline, Week 52
Secondary outcome [21] 0 0
Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 16
Assessment method [21] 0 0
Percentage of participants classified as OMERACT-OARSI responders at Week 16. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement = 50% and absolute reduction = 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement = 50% and absolute reduction = 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement = 20% and absolute reduction (in normalized 0 - 100 scale) = 10 as compared to the baseline; WOMAC Function improvement = 20% and absolute reduction (in normalized 0 - 100 scale) = 10 as compared to the baseline; PGA improvement = 20% and absolute change (in normalized 0 - 100 scale) = 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.
Timepoint [21] 0 0
Week 16
Secondary outcome [22] 0 0
Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 26
Assessment method [22] 0 0
Percentage of participants classified as OMERACT-OARSI responders at Week 26. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement = 50% and absolute reduction = 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement = 50% and absolute reduction = 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement = 20% and absolute reduction (in normalized 0 - 100 scale) = 10 as compared to the baseline; WOMAC Function improvement = 20% and absolute reduction (in normalized 0 - 100 scale) = 10 as compared to the baseline; PGA improvement = 20% and absolute change (in normalized 0 - 100 scale) = 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.
Timepoint [22] 0 0
Week 26
Secondary outcome [23] 0 0
Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 52
Assessment method [23] 0 0
Percentage of participants classified as OMERACT-OARSI responders at Week 52. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement = 50% and absolute reduction = 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement = 50% and absolute reduction = 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement = 20% and absolute reduction (in normalized 0 - 100 scale) = 10 as compared to the baseline; WOMAC Function improvement = 20% and absolute reduction (in normalized 0 - 100 scale) = 10 as compared to the baseline; PGA improvement = 20% and absolute change (in normalized 0 - 100 scale) = 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.
Timepoint [23] 0 0
Week 52

Eligibility
Key inclusion criteria
1. Radiographic knee osteoarthritis with Kellgren-Lawrence Grade 2 or 3
2. Body Mass Index (BMI) 18-34 kg/m2
3. One or more clinical signs and symptoms of active inflammation in the index knee
Minimum age
35 Years
Maximum age
74 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. History of allergic reaction to any constituents of the study drug, or to any Immunoglobulin G (IgG)-containing product
2. History of anaphylactic reaction to any agent
3. Significant trauma or surgery to the index knee
4. Severe knee malalignment
5. Any uncontrolled medical illness or an unstable treatment or therapy

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
4/06/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
13/12/2016
Sample size
Target
Accrual to date
Final
350
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AbbVie
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Marc Levesque, MD
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT02087904